<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Neuromuscular Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Neuromuscular Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Нервно-мышечные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-8721</issn><issn publication-format="electronic">2413-0443</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">167</article-id><article-id pub-id-type="doi">10.17650/2222-8721-2016-6-3-17-23</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Efficacy of Cellex in patients with mild cognitive impairment</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность применения препарата Целлекс® для лечения пациентов с хронической ишемией головного мозга и умеренными когнитивными расстройствами</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Abusueva</surname><given-names>B. A.</given-names></name><name xml:lang="ru"><surname>Абусуева</surname><given-names>Б. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Evzel’man</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Евзельман</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kamchatnov</surname><given-names>P. R.</given-names></name><name xml:lang="ru"><surname>Камчатнов</surname><given-names>П. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Umarova</surname><given-names>Kh. Yu.</given-names></name><name xml:lang="ru"><surname>Умарова</surname><given-names>Х. Я.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dagestan State Medical Academy, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Дагестанская государственная медицинская академия» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.S. Turgenev Oryol State University, Medical Institute</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Орловский государственный университет им. И.С. Тургенева. Медицинский институт»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Medical Faculty, Chechen State University</institution></aff><aff><institution xml:lang="ru">Медицинский факультет ФГБОУ ВО «Чеченский государственный университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-04-16" publication-format="electronic"><day>16</day><month>04</month><year>2019</year></pub-date><volume>6</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>17</fpage><lpage>23</lpage><history><date date-type="received" iso-8601-date="2016-10-12"><day>12</day><month>10</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-10-12"><day>12</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Abusueva B.A., Evzel’man M.A., Kamchatnov P.R., Umarova K.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Абусуева Б.А., Евзельман М.А., Камчатнов П.Р., Умарова Х.Я.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Abusueva B.A., Evzel’man M.A., Kamchatnov P.R., Umarova K.Y.</copyright-holder><copyright-holder xml:lang="ru">Абусуева Б.А., Евзельман М.А., Камчатнов П.Р., Умарова Х.Я.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://nmb.abvpress.ru/jour/article/view/167">https://nmb.abvpress.ru/jour/article/view/167</self-uri><abstract xml:lang="en"><p>Background. Cognitive disorders may often lead to professional invalidisation and increasing dependence on the external assistance in every day life. Identification of patients with preserved intellectual status and social adaptation but with mild cognitive impairment (MCI) is considered to be an effective measure. MCI detection and timely initiation of treatment in most patients is essential to delay the onset of severe dementia.Objective. Investigating influence of Cellex in patients with chronic cerebral ischemia and MCI.Materials and methods. As a part of non-interventional observational comparative study we evaluated the results of Cellex administration in 90 patients with MCI. Patients were divided into 2 groups. Patients from both groups received 1 course of 10 subcutaneous injections of Cellex drug at the dose of 1 mL, and patients from group 2 received two identical courses with an interval of two months. The survey, which included psychometric testing by using special questionnaires (Mini-Mental State Examination, “Frontal Assessment Battery” and “Clock Drawing” tests, Schulte test) was performed before treatment, and at months 1 and 2 after its completion.</p><p>Results. Neuropsychological examination revealed improvement in the patients state, more pronounced after the 2nd course of therapy.Discussion. Our results provide a basis for using Cellex in patients with chronic cerebral ischemia and MCI, allowing to proceede with further studies on the optimal dosage of that drug.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>chronic cerebral ischemia</kwd><kwd>mild cognitive impairment</kwd><kwd>Cellex</kwd><kwd>neuropsychological testing</kwd><kwd>cerebrovascular disease</kwd><kwd>dementia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая ишемия головного мозга</kwd><kwd>умеренное когнитивное расстройство</kwd><kwd>Целлекс®</kwd><kwd>нейропсихологическое обследование</kwd><kwd>цереброваскулярное заболевание</kwd><kwd>деменция</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Waldemar G., Dubois B., Emre M. Alz heimer’s disease and other disorders associated with dementia. In book: European handbook of neurological management. Eds.: R. Hughes, M. Brainin, N. Gilhus. Oxford: Blackwell Publishing, 2006. 640 p.</mixed-citation><mixed-citation xml:lang="ru">Waldemar G., Dubois B., Emre M. Alz heimer’s disease and other disorders associated with dementia. In book: European handbook of neurological management. Eds.: R. Hughes, M. Brainin, N. Gilhus. Oxford: Blackwell Publishing, 2006. 640 p.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Захаров В.В., Вахнина Н.В. Когнитивные нарушения при цереброваскулярных заболеваниях. Неврология и психиатрия 2014;(1):36–43. [Zakharov V.V., Vakhnina N.V. Cognitive impairment in cerebrovascular diseases. Nevrologiya i psikhiatriya = Neurology and Psychiatry 2014;(1):36–43. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Захаров В.В., Вахнина Н.В. Когнитивные нарушения при цереброваскулярных заболеваниях. Неврология и психиатрия 2014;(1):36–43. [Zakharov V.V., Vakhnina N.V. Cognitive impairment in cerebrovascular diseases. Nevrologiya i psikhiatriya = Neurology and Psychiatry 2014;(1):36–43. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Gauthier S., Touchon J. Subclassification of mild cognitive impairment in research and clinical practice. In book: Alzheimer’s disease and related disorders. Eds.: S. Gauthier, P. Scheltens, J. Cummings. London, UK: Martin Dunitz, 2004. Pp. 61–69.</mixed-citation><mixed-citation xml:lang="ru">Gauthier S., Touchon J. Subclassification of mild cognitive impairment in research and clinical practice. In book: Alzheimer’s disease and related disorders. Eds.: S. Gauthier, P. Scheltens, J. Cummings. London, UK: Martin Dunitz, 2004. Pp. 61–69.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Левин О.С. Алгоритмы диагностики и лечения деменции. М.: МЕДпресс-информ, 2012. [Levin О.S. Аlgorithms of dementia diagnostics and treatment. Мoscow: МЕDpress-infоrm, 2012. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Левин О.С. Алгоритмы диагностики и лечения деменции. М.: МЕДпресс-информ, 2012. [Levin О.S. Аlgorithms of dementia diagnostics and treatment. Мoscow: МЕDpress-infоrm, 2012. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Гусев Е.И., Боголепова Н.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М.: МЕДпресс-информ, 2014. [Gusev Е.I., Bogolepovа N.N. Cognitive impairment in cerebrovascular disorders. Мoscow: МЕDpress-infоrm, 2014. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Гусев Е.И., Боголепова Н.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М.: МЕДпресс-информ, 2014. [Gusev Е.I., Bogolepovа N.N. Cognitive impairment in cerebrovascular disorders. Мoscow: МЕDpress-infоrm, 2014. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Гусев Е.И., Камчатнов П.Р. Пластичность головного мозга в норме и патологии. Журнал неврологии и пси хиатрии им. С.С. Корсакова 2004;(2):73–80. PMID: 15071851. [Gusev Е.I., Kamchatnov P.R. Normal and pathologic brain plasticity. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2004;(2):73–80. PMID: 15071851. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Гусев Е.И., Камчатнов П.Р. Пластичность головного мозга в норме и патологии. Журнал неврологии и пси хиатрии им. С.С. Корсакова 2004;(2):73–80. PMID: 15071851. [Gusev Е.I., Kamchatnov P.R. Normal and pathologic brain plasticity. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2004;(2):73–80. PMID: 15071851. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Ali M.R., Abo-Youssef A.M., Messiha B.A., Khattab M.M. Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxidonitrosative stress. Naunyn Schmiedebergs Arch Pharmacol 2016;389(6):637–56. DOI: 10.1007/s00210-016-1234-6. PMID: 27026404.</mixed-citation><mixed-citation xml:lang="ru">Ali M.R., Abo-Youssef A.M., Messiha B.A., Khattab M.M. Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxidonitrosative stress. Naunyn Schmiedebergs Arch Pharmacol 2016;389(6):637–56. DOI: 10.1007/s00210-016-1234-6. PMID: 27026404.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Anaeigoudari A., Soukhtanloo M., Shafei M. et al. Neuronal nitric oxide synthase has a role in the detrimental effects of lipopolysaccharide on spatial memory and synapticplasticity in rats. Pharmacol Rep 2016;68(2):243–9. DOI: 10.1016/j.pharep.2015.09.004.</mixed-citation><mixed-citation xml:lang="ru">Anaeigoudari A., Soukhtanloo M., Shafei M. et al. Neuronal nitric oxide synthase has a role in the detrimental effects of lipopolysaccharide on spatial memory and synapticplasticity in rats. Pharmacol Rep 2016;68(2):243–9. DOI: 10.1016/j.pharep.2015.09.004.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Гомазков О.А. Нейротрофические факторы мозга. М.: НИИ биомедицинской химии РАМН, 2004. 311 с. [Gomazkov О.А. Neurotrophic brain factors. Мoscow: NII biomeditsinskoy khimii RAMN, 2004. 311 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Гомазков О.А. Нейротрофические факторы мозга. М.: НИИ биомедицинской химии РАМН, 2004. 311 с. [Gomazkov О.А. Neurotrophic brain factors. Мoscow: NII biomeditsinskoy khimii RAMN, 2004. 311 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Дурнев А.Д. Исследование мутагенности и потенциальной канцерогенности препарата «белково-пептидный комплекс» (БПК) в краткосрочных тестах. М.: НИИ фармакологии им. В.В. Закусова РАМН, 2011. [Durnev А.D. Studies of mutagenecity and of potential cancerogenicity of the “protein-peptide complex substance” (PPCS) in short term tests. Моscow: NII farmakologii im. V.V. Zakusova RAMN, 2011. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Дурнев А.Д. Исследование мутагенности и потенциальной канцерогенности препарата «белково-пептидный комплекс» (БПК) в краткосрочных тестах. М.: НИИ фармакологии им. В.В. Закусова РАМН, 2011. [Durnev А.D. Studies of mutagenecity and of potential cancerogenicity of the “protein-peptide complex substance” (PPCS) in short term tests. Моscow: NII farmakologii im. V.V. Zakusova RAMN, 2011. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Романова Г.А., Шакова Ф.М., Барсков И.В. и др. Влияние целлекса на функциональные и морфологические изменения при экспериментальной фокальной ишемии префронтальной коры головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(9):52–6. PMID: 21462442. [Romanova G.А., Shakovа F.М., Barskov I.V. et al. Cellex influence on functional and morphologic changes at the experimental focal ischemia of the medial prefrontal cortex. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2010;110(9): 52–6. PMID: 21462442. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Романова Г.А., Шакова Ф.М., Барсков И.В. и др. Влияние целлекса на функциональные и морфологические изменения при экспериментальной фокальной ишемии префронтальной коры головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова 2010;110(9):52–6. PMID: 21462442. [Romanova G.А., Shakovа F.М., Barskov I.V. et al. Cellex influence on functional and morphologic changes at the experimental focal ischemia of the medial prefrontal cortex. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2010;110(9): 52–6. PMID: 21462442. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Пизова Н.В., Соколов М.А., Измайлов И.А. Целлекс в лечении больных с острым нарушением мозгового кровообращения: результаты российского многоцентрового сравнительного откры того клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова 2014;114(5):22–6. PMID: 24988954. [Pizovа N.V., Sokolov М.А., Izmaylov I.А. Cellex in the treatment of patients with acute cerebrovascular accident: results of Russian multicenter comparative open clinical studies. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2014;114(5): 22–6. PMID: 24988954. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Пизова Н.В., Соколов М.А., Измайлов И.А. Целлекс в лечении больных с острым нарушением мозгового кровообращения: результаты российского многоцентрового сравнительного откры того клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова 2014;114(5):22–6. PMID: 24988954. [Pizovа N.V., Sokolov М.А., Izmaylov I.А. Cellex in the treatment of patients with acute cerebrovascular accident: results of Russian multicenter comparative open clinical studies. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2014;114(5): 22–6. PMID: 24988954. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Коваленко А.В., Сафронова М.Н. Влияние целлекса на восстановление когнитивных и речевых нарушений в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова 2015;115(1):40–4. PMID: 25909788. [Kovalenko А.V., Safronovа М.N. Cellex influence on the restoration of cognitive and speech deteriorations in the acute period of stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova =S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(1): 40–4. PMID: 25909788. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Коваленко А.В., Сафронова М.Н. Влияние целлекса на восстановление когнитивных и речевых нарушений в остром периоде инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова 2015;115(1):40–4. PMID: 25909788. [Kovalenko А.V., Safronovа М.N. Cellex influence on the restoration of cognitive and speech deteriorations in the acute period of stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova =S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(1): 40–4. PMID: 25909788. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Камчатнов П.Р., Чугунов А.В., Умарова Х.Я. Метаболическая терапия ишемического инсульта. Фарматека 2015; 302(9):20–7. [Kamchatnov P.R., Chugunov А.V., Umarova Kh.Ya. Меtabolic therapy of the ischemic stroke. Farmateka =Pharmateca 2015;302(9):20–7. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Камчатнов П.Р., Чугунов А.В., Умарова Х.Я. Метаболическая терапия ишемического инсульта. Фарматека 2015; 302(9):20–7. [Kamchatnov P.R., Chugunov А.V., Umarova Kh.Ya. Меtabolic therapy of the ischemic stroke. Farmateka =Pharmateca 2015;302(9):20–7. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Бельская Г.Н., Крылова Л.Г., Соко лов М.А., Измайлов И.А. Возможности коррекции речевых расстройств в остром периоде ишемического инсульта с помощью нейропротективной терапии. Журнал неврологии и психиатрии им. С.С. Кор сакова 2015;115(9):60–3. DOI: 10.17116/jnevro20151159260-63. [Bel’skaya G.N., Krylovа L.G., Sokolov М.А., Izmaylov I.А. Possibilities for the correction of speech disorders with the neuroprotective therapy in stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(9):60–3. DOI: 10.17116/jnevro20151159260-63. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Бельская Г.Н., Крылова Л.Г., Соко лов М.А., Измайлов И.А. Возможности коррекции речевых расстройств в остром периоде ишемического инсульта с помощью нейропротективной терапии. Журнал неврологии и психиатрии им. С.С. Кор сакова 2015;115(9):60–3. DOI: 10.17116/jnevro20151159260-63. [Bel’skaya G.N., Krylovа L.G., Sokolov М.А., Izmaylov I.А. Possibilities for the correction of speech disorders with the neuroprotective therapy in stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(9):60–3. DOI: 10.17116/jnevro20151159260-63. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Левин О.С. Алгоритмы диагностики и лечение деменции. 5-е издание. М.: МЕД-пресс-информ, 2012. [Levin О.S. Аlrorithms of dementia diagnostics and treatment. 5th ed. Мoscow: МЕDpress-inform, 2012. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Левин О.С. Алгоритмы диагностики и лечение деменции. 5-е издание. М.: МЕД-пресс-информ, 2012. [Levin О.S. Аlrorithms of dementia diagnostics and treatment. 5th ed. Мoscow: МЕDpress-inform, 2012. (In Russ.)].</mixed-citation></citation-alternatives></ref></ref-list></back></article>
